Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ampio nets $63.6mm via follow-on

Executive Summary

Two months after spinning off its sexual dysfunction business into Vyrix Pharmaceuticals Inc., Ampio Pharmaceuticals Inc. (creating drugs and devices aimed at inflammatory conditions for which there are limited treatment options) netted $63.6mm through the follow-on public sale of 9.8mm common shares (including the overallotment) at $7 each. The company will use some of the money to finish clinical trials and submit regulatory filings for its Ampion knee osteoarthritis treatment and Optina for diabetic macular edema.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Monitoring Equipment & Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies